Fresenius Group Overview

The Health Care Group
Stories
Archive „Stories“
Investors
Contact

Fresenius SE & Co. KGaA

Investor Relations & Sustainability

+49 (0) 6172 608-2485
ir-fre@fresenius.com
Media
- News
- Social Media
- Calendar
- Contacts
- Media Center
Contact

Matthias Link

Senior Vice President Corporate Communications

T: +49 (0) 6172 608-2872
matthias.link@fresenius.com
Careers
Menu
Filter results
- Chapter
- Format
  - Website (0)
  - PDF (0)
Share
- Facebook
- Twitter
- LinkedIn
- Xing
- E-Mail
Services
- Deutsch
- Print
- Contact
- RSS

Q3 2021 Results

Fresenius improves FY/21 Group guidance for the second time after good Q3 results

More information

Highlights

Financial Highlights Q3/21

Sales

€ 9324 m

+5%¹

Q3/20: €8,918 m

Dividend

€ 0.88

+5%

FY/19: €0.84

EBIT²

€ 1041 m

-6%¹

Q3/20: €1,113 m

Employees

314,852

Dec. 31, 2020: 311,269

Net Income^{2, 3}

€ 435 m

+2%¹

Q3/20: €427 m

Earnings per Share^{2, 3}

€ 0.78

+1%¹

Q3/20: €0.77

¹ In constant currency

² Before special items
³ Net income attributable to shareholders of Fresenius SE & Co. KGaA

Business Segments
- Stronger than projected headwind from COVID-19 effects with significantly increased patient excess mortality due to global spread of Delta variant
- Organic growth continued with 1%
- Financial targets for FY 2021 confirmed, expectation to reach lower end of the guidance ranges for revenue and net income
Read more (PDF)
Business Segments
- North America with healthy organic sales growth; EBIT growth only hindered by a non-cash one-time effect
- Solid organic sales growth in Europe supported by ongoing recovery of elective treatments
- Continued strong Emerging Markets growth driven primarily by Latin America; China slowing down due to price effects post successful participation in VBP tenders
- EBIT outlook for FY/21 improved
Read more (PDF)
Business Segments
- Helios Germany with ongoing upward trend for elective treatments
- Treatment activity at Helios Spain above pre-pandemic levels
  in most medical areas
- Strong results in Latin America
- FY/21 outlook confirmed
Read more (PDF)
Business Segments
- Further acceleration of EBIT growth despite persistent COVID-19 impacts
- Project business still marked by COVID-19; order book remains at all-time high
- Good performance, particularly in the high-end service business; upward trend in elective treatments supports rehabilitation business
- FY/21 outlook confirmed
Read more (PDF)

Non-financial and Sustainability Reporting
We are committed to responsible and sustainable management as part of our corporate culture and day-to-day business practice. Only by doing so can we be perceived as a trustworthy and reliable partner in the health care sector.

Read more
Annual Report 2020
- The Fresenius Annual Report 2020 is now available as an online version with enhanced functionality and as a full-content PDF.
- In addition, we introduce our first our first online Sustainability Report, where you will find detailed information on the topic of sustainability at Fresenius.
- Detailed information on the impact of the pandemic on the Fresenius Group can be found in our online Annual Report.
Annual Report (PDF) Online Annual Report
Focus COVID-19
The importance of modern and functional health care for society became particularly clear in 2020 as a result of the COVID-19 pandemic.
Our employees worldwide have tirelessly helped to keep the clinics, dialysis centers, factories and logistics running.

Read more

News

Brief News
Fresenius Helios acquires majority stake in U.S. fertility center

The Eugin Group, part of Fresenius Helios, acquires a majority stake in the Delaware Institute for Reproductive Medicine (DIRM), a renowned fertility center in the U.S. state of Delaware that has been established for 35 years. With this acquisition, Eugin further expands its existing network in the U.S. and expects to generate additional synergies and operational efficiencies. A number of key physicians will remain minority shareholders in DIRM. Both sides have agreed not to disclose financial details.

January 10, 2022Fresenius Helios

Brief News
Fresenius Kabi modernizes production facility in France

Fresenius Kabi is investing about €35 million to modernize the company’s production facility in Louviers, France. Two sterilization units and two production lines for Freeflex® infusion bags will be housed in a 3,300-square-meter (35,500-square-foot) building being constructed on the site and will replace the existing production facilities. In this way, the company will continue to ensure the availability of these important products into the future. The modernization is scheduled for completion before the end of 2023. Fresenius Kabi employs some 370 people at the Louviers plant and has a total of about 1,500 employees in France.

December 13, 2021Fresenius Kabi
Brief News
Fresenius again with top result in climate ranking

In this year's ranking, the non-profit organization CDP has confirmed Fresenius' classification in the second-highest category B. Fresenius is thus once again one of the leading companies in the health care sector. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 590 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

December 08, 2021Fresenius

Fresenius Helios acquires oncological center and ophthalmic clinic in Colombia

November 22, 2021Fresenius Helios
Brief News
Fresenius SE & Co. KGaA again included in Dow Jones Sustainability Index

Fresenius has been included again in the Dow Jones Sustainability Index (DJSI Europe). The DJSI Europe index represents the top 20 percent based on the international investment company S&P Global’s analysis of their economic, environmental, and social performance. Fresenius achieved improvements in many categories, the most significant ones in the areas of Cybersecurity, Data Protection and Human Rights. In the area of Partnerships towards sustainable healthcare, Fresenius was awarded the maximum score in the rating 2021.

November 16, 2021Fresenius

Brief News
Fresenius Kabi enters collaboration to enhance controlled substance management in the U.S.

Fresenius Kabi and Omnicell, Inc are collaborating to provide U.S. hospitals and health systems with innovative new pharmacy technology designed to support safety and efficiency in dispensing of controlled substances in patient care areas. Omnicell has designed new cassettes for its Controlled Substance Dispenser specifically for Fresenius Kabi Simplist® MicroVault® pre-filled syringes. The new cassettes provide customers with more flexibility and enhanced options for controlled substance management. The collaboration with Omnicell is an example of the continued investment Fresenius Kabi has made in its Simplist® portfolio. The investment has resulted in more Simplist® products for customers to choose from including those that offer radio frequency identification (RFID) technology.

November 10, 2021Fresenius Kabi
Fresenius improves FY/21 Group guidance for the second time after good Q3 results

November 02, 2021Fresenius

Brief News
Fresenius Kabi enters collaboration to enhance the supply of essential medicines for U.S. Patients

Fresenius Kabi has agreed to collaborate with Phlow Corporation, a public benefit company, to expand access to affordable sterile injectables formulated for U.S. children’s hospitals and to help strengthen the supply chain for U.S.-sourced API and essential medicines. The companies will work together to supply private-labelled products, co-develop and manufacture novel products and make essential medicines rapidly available in the event of a public health emergency.

October 14, 2021Fresenius Kabi
Brief News
2022 DRG inflator for German hospitals set at 2.29%

The price increase for hospital services in Germany has been set at 2.29% for 2022. As it is subject to negotiations at the state level as well as individual hospital discounts, the final price increase on the individual hospital level will, however, be lower.

September 15, 2021Fresenius Helios

Brief News
Fresenius Helios publishes second sustainability report

Helios Germany has published its second sustainability report. The 60 pages report "Strong into the future" looks back on the complex challenges of the Corona year 2020 and shows in which areas the pandemic has driven developments for Germany’s largest private hospital operator. Helios Germany has defined four fields for its sustainability strategy: Patients, employees, the environment and compliance. Like the first report in 2019, it was drawn up based on the GRI standards of the Global Reporting Initiative and is now available in German on www.helios-gesundheit.de/nachhaltigkeit. An English version will be published soon.

September 08, 2021Fresenius Helios
Brief News
Biosimilar candidate of Fresenius Kabi shows positive results in two clinical trials

Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11456, a tocilizumab biosimilar candidate, successfully met the primary and secondary endpoints in two consecutively conducted clinical trials. For more information, please visit the Fresenius Kabi website.

September 07, 2021Fresenius Kabi

Brief News
Fresenius Helios divests Volkach clinic

Fresenius Helios sells the clinic in Volkach near Würzburg, Germany, to Remedium Healthcare. A corresponding agreement on the 40-bed hospital also includes the transfer of two associated specialist centers in the region. The transaction is a first result of the ongoing strategic review and optimization of Helios' hospital portfolio. The transaction is expected to close by the first quarter of 2022 at the latest. Both sides have agreed not to disclose financial details.

September 07, 2021Fresenius Helios
Brief News
Helios acquires two hospitals in Kassel, Germany

Helios acquires the DRK (German Red Cross) Kliniken Nordhessen in Kassel with two clinics with a total of 433 beds and an associated outpatient care center (MVZ), which generated sales of around €87 million in 2020. The DRK-Schwesternschaft remains a co-partner. Together with the existing Helios hospital in Warburg, a regional medical cluster shall be formed and expanded over the next few years. The acquisition is expected to be completed in the fourth quarter of 2021. The purchase price is 1 euro and includes the assumption of debts and the securing of liquidity for current operations and for future investments.

September 02, 2021Fresenius Helios

Fresenius raises Group earnings guidance after very strong Q2

July 30, 2021Fresenius
Fresenius signs 2 billion euros syndicated revolving credit facility with a link to sustainability

July 02, 2021Fresenius

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Temsirolimus Injection, a drug used to treat advanced renal cell carcinoma, is now available from Fresenius Kabi in the United States. This is the newest addition to the company’s portfolio of generic IV oncology products - the largest such portfolio in the U.S.

May 21, 2021Fresenius Kabi
Fresenius with good start to 2021 despite ongoing COVID-19 impact

May 06, 2021Fresenius

Fresenius successfully places bonds with a volume of 1.5 billion euros

March 23, 2021Fresenius
Michael Sen to succeed Mats Henriksson as CEO of Fresenius Kabi

March 16, 2021Fresenius Kabi

Brief News
Fresenius Kabi launches IV Drug in the U.S.

Foscarnet Sodium Injection is now available in the United States, expanding the company’s anti-viral portfolio. The drug is used in the treatment of conditions associated with immunocompromised patients.

March 15, 2021Fresenius Kabi
Fresenius achieves 2020 targets and expects healthy business development in 2021 despite ongoing COVID-19 impact

February 23, 2021Fresenius

Fresenius achieves FY/20 guidance demonstrating resilience amid the COVID-19 pandemic – Targets healthy sales growth and at least broadly stable net income year over year in FY/21

February 01, 2021Fresenius
Fresenius Helios acquires fertility services provider Eugin Group

December 21, 2020Fresenius Helios

Brief News
Fresenius improves in climate ranking

Fresenius has once again improved in this year's CDP ranking (formerly "Carbon Disclosure Project"). With a ranking in the second highest category B, Fresenius is one of the leading companies in the health care sector, both in Europe and globally. Companies in categories A and B are characterized by transparency, coordinated climate protection measures and the implementation of corresponding best-practice approaches. CDP is one of the most renowned climate and environmental rankings in the capital market. More than 515 investors use the annual results to evaluate climate protection activities and climate-related risks and opportunities of the companies assessed.

December 11, 2020Fresenius
Brief News
Fresenius Kabi launches IV Drug in the U.S.

Acetaminophen injection is now available in the United States in ready-to-administer freeflex^® bags, expanding the company’s anesthesia and analgesia portfolio. The drug is used in the hospital setting for pain management and fever reduction.

December 10, 2020Fresenius Kabi

Brief News
Fresenius Kabi launches its first specialty IV drug in the U.S.

Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company’s generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient’s home or doctor’s office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.

December 01, 2020Fresenius Kabi
Brief News
Fresenius Helios reporting figures on intensive care occupancy

Fresenius Helios has started publishing daily figures on the occupancy rate for intensive care beds in its 86 German hospitals. The website of each hospital will report the number of COVID-19 patients in the hospital’s regular and intensive care wards. It will also publish figures from the Robert Koch Institute, Germany’s national health agency, on the number of new infections in the surrounding region. Helios’ goal is to increase transparency and facilitate a data-based assessment of the pandemic at the local level. Helios Germany currently has a total of 1,300 intensive care beds across the country and could add an additional 1,000 on short notice, in the event of a sharp increase in COVID-19 hospitalizations.

November 02, 2020Fresenius Helios

Fresenius continues to demonstrate resilience amid the COVID-19 pandemic: FY/20 guidance confirmed given accelerated earnings growth in Q3

October 29, 2020Fresenius
Fresenius announces changes to Supervisory Board

October 13, 2020Fresenius

Brief News
Fresenius Helios expands reporting on quality standards

As part of its reporting on quality standards, Fresenius Helios is publishing data on the length of patient stays, patient security and antibiotic use in the company’s German hospitals for the first time. Data from every Helios hospital is compiled in a total of 46 quality categories, including the frequency of surgical interventions and their results, and then published annually. The comparing of different hospitals’ statistics through the Quality Medicine Initiative yields specific, concrete improvements that can be implemented in day-to-day hospital operations. The initiative, which was jointly founded by Fresenius Helios, now includes more than 400 hospitals in Germany and Switzerland.

October 09, 2020Fresenius Helios

Disclaimer All News

Library

All Financial Reports

Follow us

The Health Care Group

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com

Contacts

Visit us